Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
复制标题
DOI：
10.1002/cncr.24746
复制
发表时间：
2010-02-01
期刊：
影响因子：
6.2
通讯作者：
DeMichele, Angela
中科院分区：
文献类型：
--
作者：
Su, H. Irene;Sammel, Mary D.;Green, Jamie;Velders, Luke;Stankiewicz, Corrie;Matro, Jennifer;Freeman, Ellen W.;Gracia, Clarisa R.;DeMichele, Angela
关键词：
在生育年龄较晚的乳腺癌幸存者中，需要“实时”检测化疗后卵巢功能的生物标记物。目的是确定抗苗勒氏激素(AMH)和抑制素B是否是这样的生物标志物。我们通过比较癌症幸存者和年龄匹配的对照组女性来检验乳腺癌治疗是否对AMH和抑制素B产生影响。我们确定了这些激素与化疗后月经模式之间的关系。127例诊断为绝经前的I-III期乳腺癌患者在化疗后入选并进行随访。主要终点是化疗相关的闭经(化疗后12个月闭经的CRA，≥)。配对分析比较了癌症受试者和年龄匹配的对照组受试者的AMH、抑制素B和卵泡刺激素(FSH)水平。评估了激素、CRA状态和CRA状态随时间的变化之间的关系。化疗时的中位年龄为43.2岁(范围26.7-57.8)。在登记时，化疗后的中位随访期为2.1年，55%的受试者患有CRA。与年龄匹配的对照组相比，癌症患者的AMH(p=0.004)和抑制素B(p<；0.001)显著降低，卵泡刺激素(p<；0.001)显著升高。AMH(p=0.002)和抑制素B(p=0.001)与CRA的风险显著相关，即使在控制了FSH之后也是如此。继发CRA的月经受试者AMH显著降低(p=0.03)，FSH显著升高(p=0.04)。AMH和抑制素B是晚期生育年龄乳腺癌幸存者化疗后卵巢功能的另外两项指标。随着进一步的研究和验证，这些激素可能会补充目前有限的评估和预测化疗后卵巢功能的工具
In late reproductive-aged breast cancer survivors, there is a need for “real-time” biomarkers of post-chemotherapy ovarian function. The objective was to determine if anti-mullerian hormone (AMH) and inhibin B are such biomarkers. We tested if AMH and inhibin B were impacted by breast cancer treatment by comparing cancer survivors to age-matched control women. We determined the association between these hormones and post-chemotherapy menstrual pattern. 127 breast cancer patients with Stages I–III disease, premenopausal at diagnosis, were enrolled post-chemotherapy and followed. The primary endpoint was chemotherapy related amenorrhea (CRA, ≥12 months of amenorrhea after chemotherapy). Matched pair analyses compared AMH, inhibin B and follicle stimulating hormone (FSH) levels between cancer and age-matched control subjects. Associations between hormones, CRA status and change in CRA status over time were assessed. Median age at chemotherapy was 43.2 years (range 26.7–57.8). At enrollment, median follow up since chemotherapy was 2.1 years and 55% of subjects had CRA. Compared to age-matched controls, cancer subjects had significantly lower AMH (p=0.004) and inhibin B (p<0.001) and higher FSH (p<0.001). AMH (p=0.002) and inhibin B (p=0.001) were significantly associated with risk of CRA even after controlling for FSH. AMH was significantly lower (p=0.03) and FSH was significantly higher (p=0.04) in menstruating subjects who developed subsequent CRA. AMH and inhibin B are two additional measures of post-chemotherapy ovarian function in late reproductive-aged breast cancer survivors. With further research and validation, these hormones may supplement limited current tools for assessing and predicting post-chemotherapy ovarian function
登录
查看更多内容
影响因子：
2.4
作者：
Anders, Carey;Marcom, P. Kelly;Blackwell, Kimberly
通讯作者：
Blackwell, Kimberly
DOI：
10.1097/00042192-200512020-00005
发表时间：
2005-01-01
影响因子：
2.7
作者：
Gracia, CR;Sammel, MD;Nelson, DB
通讯作者：
Nelson, DB
影响因子：
6.1
作者：
Fanchin, R;Taieb, J;Bouyer, J
通讯作者：
Bouyer, J
影响因子：
6.7
作者：
de Vet, A;Laven, JSE;Fauser, BCJM
通讯作者：
Fauser, BCJM
影响因子：
45.3
作者：
Goodwin, PJ;Ennis, M;Hood, N
通讯作者：
Hood, N